Quick answer: Newer Alzheimer’s treatments such as Kisunla, the brand name for donanemab azbt, can reduce beta amyloid plaques and slow cognitive and functional decline in some people with early symptomatic Alzheimer’s disease. They are not cures and they are not appropriate for everyone. Even when a person qualifies for treatment, families may still need help with personal care, meals, routines, companionship, mobility, supervision, transportation, and caregiver relief at home.
Educational note: This article provides general information and is not medical advice. Diagnosis, treatment eligibility, imaging, medication decisions, infusion care, and clinical monitoring belong with qualified healthcare professionals. Call 911 for a medical emergency.
A hopeful Alzheimer’s headline can change the mood of an entire family. In recent years, disease modifying treatments have moved the conversation beyond symptom management alone. That progress matters. It also creates a new kind of confusion for families who are already helping a parent or spouse through memory loss.
If a treatment can remove much of the amyloid seen on a brain scan, does that mean the person is cured? If treatment slows decline, will bathing, meals, repeated questions, wandering concerns, transportation, or nighttime supervision suddenly become easier? And if the medical plan is changing, what should the family change at home?
The clearest way to think about these questions is to separate medical treatment from daily living support. Medical specialists diagnose Alzheimer’s disease, determine whether a treatment is appropriate, prescribe it, and monitor risks. Alzheimer’s and dementia care at home focuses on the practical routines that still have to happen between appointments.
What Has Changed in Alzheimer Treatment?
Kisunla is the brand name for donanemab azbt, an amyloid beta directed antibody approved by the U.S. Food and Drug Administration for Alzheimer’s disease. The FDA approval information for Kisunla states that treatment should be initiated in people with mild cognitive impairment or mild dementia stage of disease, the population studied in the clinical trials.
Donanemab is different from medications that are used mainly to manage symptoms. It targets beta amyloid, a protein that can accumulate into plaques in the brains of people with Alzheimer’s disease. By reducing amyloid, the treatment acts on part of the underlying disease process.
The National Institute on Aging overview of treatment progress notes that donanemab received traditional FDA approval in 2024 after earlier progress with lecanemab. This is an important change in Alzheimer’s treatment, but the benefit must be described accurately: these therapies can slow decline for some people with early disease. They do not restore every lost ability or eliminate the disease.
Does Removing Amyloid Mean Alzheimer Disease Is Cured?
No. Amyloid reduction is not the same as an Alzheimer’s cure. Alzheimer’s disease involves more than amyloid plaques. It is also associated with abnormal tau changes and progressive damage to brain cells and their connections. A person can have a strong reduction in amyloid and still have memory, thinking, judgment, communication, or functional difficulties.
That distinction is essential when families see a dramatic treatment story. The responsible interpretation is that medicine now has disease modifying options for certain people in the early stages of Alzheimer’s disease. It is not evidence that the everyday consequences of the disease disappear when a scan improves.
For a family, this means hope and planning can exist at the same time. It is reasonable to feel encouraged by treatment progress while also building a realistic care plan for the routines that remain difficult today.
Who May Be Considered for Donanemab?
A memory complaint alone does not determine eligibility. The FDA indication focuses on mild cognitive impairment or mild dementia stage of Alzheimer’s disease, and amyloid pathology is confirmed before treatment. The treating clinician considers the person’s diagnosis, medical history, imaging, medications, risk factors, expected benefit, and treatment goals.
Safety monitoring is also part of the decision. The current FDA prescribing information for Kisunla contains a boxed warning for amyloid related imaging abnormalities, known as ARIA. ARIA can involve brain swelling or bleeding. It is often asymptomatic, but serious and life threatening events can occur. The label also describes MRI monitoring and increased ARIA risk in some patients.
This is why a home care article should never tell a reader that a family member is a good candidate for donanemab. That decision belongs with the medical team. Families can instead prepare useful questions: What stage of disease is present? How was amyloid confirmed? What benefit is realistic? What monitoring is required? What symptoms require urgent medical attention? How will treatment fit with the person’s other health conditions and medications?
Why Can Support at Home Still Matter When Treatment Is Working?
A disease modifying treatment can target amyloid without solving every difficulty that already exists in daily life. Memory and thinking changes can affect sequencing, judgment, initiation, communication, orientation, and the ability to complete familiar tasks. A person may recognize the bathroom but forget the steps needed to get ready. They may say they already ate because they do not remember missing breakfast. They may become anxious when a familiar routine changes.
Those problems are not proof that treatment has failed. They are examples of the gap between a medical treatment plan and the work of living at home with Alzheimer’s disease. Families often carry that workload quietly until it becomes too much for one spouse or adult child.
Personal Care Can Become a Daily Negotiation
Bathing, dressing, grooming, oral hygiene, and toileting may become harder for reasons that have little to do with physical strength. The person may forget why the task is necessary, feel exposed, misinterpret assistance, or become overwhelmed when several instructions are given at once.
When hands-on help is needed, personal care support can assist with established daily routines such as bathing, dressing, grooming, and toileting while the family and care team preserve as much independence as is practical.
The caregiver’s job is not to argue the person into remembering correctly. A calmer approach is to simplify the task, use familiar cues, protect privacy, and give the person time to participate. If confusion or behavior changes suddenly, the family should not automatically assume Alzheimer’s disease is the cause. Sudden changes can have medical causes and should be addressed according to the person’s healthcare plan.
Meals Can Break Down Before Families Notice
A person may still say they can cook while quietly losing track of groceries, food safety, appliance use, or the sequence of preparing a meal. Others eat less because the steps of choosing food, preparing it, sitting down, and finishing the meal have become difficult.
Angels Instead also provides meal preparation support for families who need practical help around shopping, preparation, serving, and established dietary routines.
Non medical home care should follow dietary instructions already provided by the healthcare team. A caregiver can help carry an approved routine into the day, but should not invent a therapeutic diet or make clinical nutrition decisions.
Companionship Is Not a Memory Test
Alzheimer’s disease changes memory, but it does not erase the need for connection. Familiar music, photographs, conversation, folding laundry, gardening, a short walk, or sitting together on the porch can give the day structure without demanding perfect recall.
Thoughtful companionship care can be built around the person’s preferences and history. The goal is meaningful presence and engagement, not repeatedly correcting mistakes or testing what the person remembers.
This matters because families sometimes measure a good day by how much the person remembered. A better measure may be whether the person felt calm, included, respected, and able to participate at their current level.
Mobility Needs May Change Separately From Memory
Cognitive changes can affect judgment and safety awareness even when a person remains physically strong. Someone may forget to use a walker, stand before help arrives, misjudge a chair, or have difficulty following a multi step transfer instruction. Physical changes can later add another layer.
Families should follow professional recommendations for assistive devices, rehabilitation, and home modifications. A non medical caregiver can support the established mobility routine and provide assistance that fits the care plan and agency scope.
Family Caregivers Still Need Coverage
One of the easiest mistakes to make after hearing good treatment news is to assume the caregiving workload should now feel manageable. Treatment does not automatically create coverage for work hours, medical appointments, errands, sleep, family responsibilities, or the periods when the person cannot be left alone.
Planned in-home respite care can give a spouse or adult child protected time away from direct caregiving while established routines continue at home.
Respite works best when it covers the part of the week that is actually difficult. For one family that may be morning personal care. For another it may be the workday, evening routines, or the hours needed for the primary caregiver to attend their own appointments.
Some Families Need More Hours as Needs Change
Alzheimer’s care is rarely static. A few scheduled visits may be enough at one stage. Later, changes in supervision, nighttime activity, wandering risk, personal care, mobility, or family availability may create longer coverage gaps.
Families comparing different levels of support can review the current Angels Instead home care services and discuss whether scheduled assistance, longer shifts, or more continuous coverage fits the person’s present needs.
The diagnosis alone should not determine the schedule. Two people with Alzheimer’s disease can need very different amounts of help. A useful care plan starts with what is actually happening at home: which tasks are being missed, when risk increases, what the person can still do independently, and where the family cannot provide reliable coverage.
What Should Families Observe While Treatment Continues?
The medical team determines clinical monitoring. At home, families can make their observations more useful by documenting specific changes rather than relying on a general impression that the person seems better or worse.
- Is the person completing meals or leaving food untouched?
- Are bathing, dressing, or toileting routines requiring more prompting or hands on help?
- Has walking, balance, or transfer assistance changed?
- Is the person sleeping at different times or becoming more active at night?
- Are familiar routines taking longer or causing more distress?
- Has there been a sudden change from the person’s usual behavior or level of alertness?
These observations do not diagnose whether a drug is working. They can help families explain everyday function to clinicians and help a home care team adjust non medical routines when needs change.
How Angels Instead Fits Into the Care Plan
Angels Instead currently specializes in non medical personal care and daily living support. Its role is not to diagnose Alzheimer’s disease, determine treatment eligibility, prescribe donanemab, administer Alzheimer’s infusions, interpret brain scans, or change medications.
Its role is the practical side of living at home. The current Angels Instead FAQ lists non medical support including personal care, companionship, meal preparation, mobility assistance, dementia care, and around the clock care options. It also explains that care plans can be adjusted as needs change.
This distinction protects families from an unnecessary either or choice. A person may receive specialist care, imaging, medications, and other clinical services while also receiving non medical help with the routines that make daily life possible.
Questions to Ask Before Adding Alzheimer’s Care at Home
- Which routines are becoming inconsistent, unsafe, or exhausting for the family?
- Does the person need reminders, supervision, hands on assistance, companionship, or a combination?
- What time of day creates the biggest coverage gap?
- Which tasks must remain with licensed healthcare professionals?
- What routines, preferences, communication approaches, and triggers should a caregiver know before the first visit?
- How will the family share meaningful changes without turning normal home care into constant surveillance?
- What is the backup plan if the usual family caregiver is unavailable?
- When should the care schedule be reassessed as needs or treatment plans change?
Frequently Asked Questions
Does Kisunla cure Alzheimer’s disease?
No. Kisunla, or donanemab azbt, is a disease modifying treatment that targets beta amyloid. It can slow cognitive and functional decline in some people with early symptomatic Alzheimer’s disease, but it is not a cure.
Can amyloid plaques be reduced while memory problems continue?
Yes. Amyloid reduction and everyday cognitive function are related but they are not the same outcome. Alzheimer’s disease involves multiple brain changes, and a person can continue to have memory or functional difficulties even after substantial amyloid reduction.
Is donanemab appropriate for every person with Alzheimer’s disease?
No. FDA labeling focuses on people with mild cognitive impairment or mild dementia stage of Alzheimer’s disease, the population studied in the clinical trials. A qualified clinician must determine whether treatment is appropriate for an individual.
What is ARIA?
ARIA means amyloid related imaging abnormalities. It can involve brain swelling or bleeding and is an important risk associated with amyloid targeting antibodies. The prescribing clinician determines required imaging, monitoring, and treatment decisions.
Can someone receive medical Alzheimer’s treatment and home care at the same time?
Yes. Medical treatment and non medical home care address different needs. The medical team manages diagnosis, medication, imaging, and clinical monitoring. Home care can support daily routines, personal care, meals, companionship, mobility, supervision, and family respite.
When should a family consider Alzheimer’s home care?
Consider discussing home care when everyday routines are no longer being managed consistently, when the person needs more supervision or hands on assistance, or when family caregivers cannot reliably cover the hours of care that are now needed.
The Bottom Line
New Alzheimer’s treatments are meaningful progress. Families should be able to feel hopeful about that progress without being pushed into exaggerated claims. Donanemab can reduce amyloid and slow decline for some people with early symptomatic Alzheimer’s disease, but it does not erase every cognitive change or every practical care need.
The medical team should remain responsible for diagnosis, treatment, imaging, medication decisions, and clinical monitoring. At home, the family still needs a workable plan for meals, personal care, routines, mobility, companionship, supervision, transportation, and caregiver coverage.
If those daily needs are becoming difficult to manage consistently, request a home care assessment from Angels Instead. Share what has become harder, when coverage is needed, and what the person can still do independently. The goal is not to replace the medical plan. It is to build practical support around everyday life at home.
